


Introducción a la Inmunoterapia

Belen Garcia Giner

Especialista en Clinica Medica

Residente de Oncologia Clinica


Hospital Aleman de Buenos Aires



Immuno-oncologia (IO): Cambio de paradigma

TRADITIONAL
ONCOLOGY
VIEW

**A CANCER THAT
GROW**



IMMUNO-
ONCOLOGY
VIEW

**A BODY THAT
LET A CANCER
GROW**

Immunotherapy is making history




- 400.000 cancer patients
- PD1-pathway clinical trials

2018 Nobel Prize in Medicine Awarded to 2 Cancer Immunotherapy Researchers





The Nobel Prize for Physiology and Medicine was awarded to James P. Allison, left, and Tasuku Honjo on Monday for their work on cancer research. Jonathan Hackett/Agence France-Presse — Getty Images

IO activity for over 20 Different Advanced Cancers




Immunotherapy targets immune system







Interacción del cáncer y el sistema inmune: Ciclo cáncer - inmunidad



Interacción PD-1/PDL-1: Inhibe activación de las células T




Interacción PD-1/PDL-1: Inhibe activación de las células T



**PD-L1 INHIBE LA ACTIVIDAD
CITOTÓXICA DE LAS
CÉLULAS T EN EL
MICROAMBIENTE TUMORAL**

Immunotherapy targets immune system



Immunotherapy targets immune system

Know your Immune Checkpoint Antibodies

Anti-CTLA-4

Ipilimumab
(BMS)
Tremelimumab
(AZ)

Approved



Anti-PD-1

Nivolumab
(BMS)
Pembrolizumab
(MSD)

Approved



Anti-PD-L1

Atezolizumab
(MPDL3280A)

Durvalumab
(MEDI4736)

Avelumab
(PF-06834635
/MSB0010718C)


Approved



Courtesy of S.Champiat

La Inmunoterapia aumenta la tasa y duración de respuesta y mejora la sobrevida global de los pacientes

Immunogenicidad





PD-L1 status





PD-L1 + → mejor respuesta?


Mayor tasa y duración de respuesta




Aumento Sobrevida Global






Spectrum of immune related Events




It's not about the frequency...it's about diversity !





Spectrum of immune related Events



Spectrum of immune related Events



Reported irAE distribution, immunoTOX board



VOLUME 36 • NUMBER 17 • JUNE 10, 2018

JOURNAL OF CLINICAL ONCOLOGY

ASCO SPECIAL ARTICLE



Annals of Oncology 28 (Supplement 4): i119–i142, 2017
doi:10.1093/annonc/mdx225

CLINICAL PRACTICE GUIDELINES

Management of toxicities from immunotherapy:
ESMO Clinical Practice Guidelines for diagnosis,
treatment and follow-up[†]

J. B. A. G. Haanen¹, F. Carbone², C. Robert³, K. M. Kerr⁴, S. Peters⁵, J. Larkin⁶ & K. Jordan⁷, on behalf of
the ESMO Guidelines Committee*

- *Inmunoterapia como resultado de un cambio de paradigma en la oncología*
- *Efecto en mas de 20 tipos de canceres distintos, los mas inmunogenicos: NSCLC y melanoma*
- *Cambio la evolución del cáncer de pulmón: largos sobrevividores > 5 anos!!!*
- *Múltiples ensayos clínicos on-going: combinaciones*
- *Efectos adversos menos frecuentes, variados y potencialmente graves: detección a tiempo*



belgarciaginer@gmail.com

Gracias!!